These actions will benefit from new habits
The wave is about to become a wave. At this time, there are numerous barriers for people considering treating their…
investment strategy
Eli Lilly investors shouldn't worry that rival Novo Nordisk has the first anti-obesity pill on sale
Jim Cramer says not to worry about Novo Nordisk's lead over Club that has Eli Lilly in the obesity pill…
How donors, access and polls led Trump to reclassify marijuana
President Donald Trump's decision Thursday to sign an executive order easing federal restrictions on marijuana (and clearing the way for…
Trump reclassifies cannabis to Schedule III, easing restrictions on marijuana
US President Donald Trump sits in the Oval Office to sign executive orders, at the White House in Washington, DC,…
Trump confirms possible drug reclassification, but stocks fall
Bill Schmitt Jr. (C) joins cannabis reform protesters outside the White House to call on US President Joe Biden “to…
Why Wall Street and Jim Cramer Think Danaher Stock Is 'Ready to Play'
Danaher is finally turning the corner. CNBC's Jim Cramer sees it. Wall Street does it too. Life sciences stocks are…
A biotech stock for investors who fear investing in the risky industry
Citigroup believes investors should consider Ligand Pharmaceuticals for a more conservative bet on the biotech industry. The bank initiated the…
Jim Cramer has faith in Danaher's turnaround as life sciences come back to life
Life sciences stocks are experiencing a resurgence, and that's good news for Danaher. Connecting the dots with better times ahead…
Goldman Sachs Acquires ETF Firm Innovator Capital Management for $2 Billion
David Solomon, CEO of Goldman Sachs. Bloomberg | Bloomberg | fake images Goldman Sachs on Monday said it agreed to…
We're raising our Eli Lilly price target – what a difference a quarter makes!
Eli Lilly shares rose Thursday after the drugmaker posted a strong third quarter, boosted by sales of its popular GLP-1…